| |
Luminal A |
Luminal B |
HER2-enriched |
Basal-like |
Claudin-low |
| Hormonal receptors status |
ER+ PR+/- |
ER+ PR+/- |
ER+/- PR+/- |
ER- PR- |
ER- PR- |
| HER-2 |
negative |
negative /positive |
positive |
negative |
negative |
| Ki-67 |
<14% |
>14% |
>14% |
>14% |
>14% |
| cytokeratins |
8/18 + |
8/18 + |
|
5/6 + |
5/6/14 + 8/18/19 - |
| Claudins |
negative |
negative |
negative |
negative |
3/4/7 + |
| Immune system |
CD44-/CD20+ |
CD44-/CD20+ |
CD44-/CD20+ |
CD44-/CD20+ |
CD44+/CD20+ CD49f + |
| Others |
ER, Reg, GATA-3,LIV-1, CCND-1,X-BOX-1,FOXA-1 |
ER, proliferation genes, sometimes HER-2 positive |
TP53 mut. GRB-7 |
BCRA1 mut ALDH-1+ |
EpCAM –, Cadherin -, MUC-1 - ALDH-1 MaSCs enriched |
| Clinical feature |
Low grade, lower risk of recurrence, more sensible to endocrine therapy than chemotherapy. Most common form of breast cancer |
Moderate grade compared to luminal A, more risk of recurrence, sensible to endocrine therapy and chemotherapy |
Frequently high grade Higher risk of recurrence Usually axilar nodes positives at diagnosis |
High grade Higher risk of recurrence Responsive to chemotherapy Associated BCRA mutation carries |
High grade Higher risk of recurrence Responsive to chemotherapy |
| Target treatment |
Endocrine therapy (Tamoxifen/IA/aLHRH) |
Endocrine therapy (Tamoxifen/IA/aLHRH) |
Anti-HER2 (Trastuzumab, lapatinib) |
Ongoing trials |
Ongoing trials |
